Venetoclax Drives Significant Shifts in BIM and BCL-2 but not MCL-1 Gene Expression in a Mouse Model of Acute Lymphoblastic Leukemia.
Background: T and B acute lymphoblastic leukemia (T, B-ALL) has seen improved survival rates with intensified chemotherapy, but therapy-resistant or refractory ALL remains a significant clinical challenge. This study examined the inhibitory effects of Venetoclax drug on the apoptosis gene to explore...
| Publicado en: | Middle East Journal of Cancer Vol. 17; no. 1; pp. 9 - 20 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Middle East Journal of Cancer
Jan2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193694179&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 193694179 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20086709 B7LE jtl: Middle East Journal of Cancer issn: 20086709 maglogo: N pubinfo: dt: Jan2026 vid: 17 iid: 1 pid: 67247 pub: Middle East Journal of Cancer artinfo: ui: 193694179 193694179 193694179 10.30476/mejc.2025.104911.2214 193694179 ppf: 9 ppct: 11 formats: fmt: @attributes: type: P tig: atl: Venetoclax Drives Significant Shifts in BIM and BCL-2 but not MCL-1 Gene Expression in a Mouse Model of Acute Lymphoblastic Leukemia. aug: au: Tari, Kaveh Abroun, Saied affil: Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran sug: subj: Leukemia, Lymphocytic, Acute Drug Therapy Antineoplastic Agents Administration and Dosage Gene Expression Profiling Proteins Models, Biological Apoptosis Drug Efficacy Human Animal Studies Mice Descriptive Statistics Experimental Studies Reverse Transcriptase Polymerase Chain Reaction Prospective Studies RNA Spectrophotometry Flow Cytometry Data Analysis Software T-Tests ab: Background: T and B acute lymphoblastic leukemia (T, B-ALL) has seen improved survival rates with intensified chemotherapy, but therapy-resistant or refractory ALL remains a significant clinical challenge. This study examined the inhibitory effects of Venetoclax drug on the apoptosis gene to explore its potential as a novel therapeutic approach for treating human T, B-ALL. Method: This was a preclinical experimental study. Firstly, samples were collected from a leukemia patient, followed by isolating blast cells that were injected into primary mice. The sample was obtained from mice in 1, 8 and 14 days; the CD45 human was quantified using flow cytometry to confirm the development of leukemia. Spleen cells from the primary mice were isolated and injected into the secondary mice. After 14 days, the Venetoclax drug was administered to the mouse models for 21 days. Subsequently, mouse spleen cells were gathered, and the expression of genes associated with apoptosis was assessed. A two-tailed t-test was performed to compare the expression of apoptotic genes between the control and Venetoclax-treated groups. Results: Our findings indicated a decrease in the expression of the B-cell lymphoma 2 (BCL-2) gene, while the expression of the BCL-2-interacting mediator (BIM) of cell death gene exhibited an augmentation. The level of expression of the MCL-1 (Myeloid leukemia 1) gene did not display any significant divergence compared with the control group. Conclusion: Venetoclax drug shows potential therapeutic potential in B and T-ALL, increasing BIM expression and decreasing BCL-2, but further investigation and clinical trial studies are needed. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|